References

8 References

1. Schadendorf, D., et al., *Melanoma.* The Lancet, 2018. **392**(10151): p. 971-984.
2. Arnold, M., et al., *Global burden of cutaneous melanoma in 2020 and projections to 2040.* JAMA dermatology, 2022. **158**(5): p. 495-503.
3. Gilchrest, B. and A. Geller, *The pathogenesis of melanoma induced by ultraviolet radiation-Reply.* New England Journal of Medicine 1999. **341**(10): p. 766-767.
4. Berwick, M., et al., *Melanoma epidemiology and prevention*. Vol. 167. 2016: Springer.
5. Ali, Z., N. Yousaf, and J. Larkin, *Melanoma epidemiology, biology and prognosis.* European Journal of Cancer Supplements, 2013. **11**(2): p. 81-91.
6. Rastrelli, M., et al., *Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification.* In vivo, 2014. **28**(6): p. 1005-1011.
7. Potrony, M., et al., *Update in genetic susceptibility in melanoma.* Annals of translational medicine, 2015. **3**(15): p. 210.
8. de Snoo, F.A. and N.K. Hayward, *Cutaneous melanoma susceptibility and progression genes.* Cancer Letters, 2005. **230**(2): p. 153-186.
9. Postow, M.A., O. Hamid, and R.D. Carvajal, *Mucosal melanoma: pathogenesis, clinical behavior, and management.* Current oncology reports, 2012. **14**: p. 441-448.
10. Li, J., Y. Zhang, and J. Tao, *Targeted nanoparticles for drug delivery to melanoma: from bench to bedside.* Nanoscience in Dermatology, 2016: p. 203-215.
11. Russo, A.E., et al., *Melanoma: molecular pathogenesis and emerging target therapies.* International journal of oncology, 2009. **34**(6): p. 1481-1489.
12. Hartman, M.L. and M. Czyz, *MITF in melanoma: mechanisms behind its expression and activity.* Cellular and Molecular Life Sciences, 2015. **72**: p. 1249-1260.
13. Li, J., et al., *Recent advances in targeted nanoparticles drug delivery to melanoma.* Nanomedicine: Nanotechnology, Biology and Medicine, 2015. **11**(3): p. 769-794.
14. Kratz, F., P. Senter, and H. Steinhagen, *Drug delivery in oncology: from basic research to cancer therapy*. Vol. 3. 2013: John Wiley & Sons. 1822.
15. Albuquerque, K.R.S., et al., *Applicability of plant extracts in preclinical studies of melanoma: A systematic review.* Mediators of Inflammation, 2018. **2018**(1): p. 6797924.
16. Dumitraș, D.-A. and S. Andrei, *Recent advances in the antiproliferative and proapoptotic activity of various plant extracts and constituents against murine malignant melanoma.* Molecules, 2022. **27**(8): p. 2585.
17. Fraihat, A., et al., *Inhibitory effects of methanol extracts of selected plants on the proliferation of two human melanoma cell lines.* Tropical Journal of Pharmaceutical Research, 2018. **17**(6): p. 1081-1086.
18. Žarković, N., et al., *Comparison of the effects of Viscum album lectin ML-1 and fresh plant extract (Isorel) on the cell growth in vitro and tumorigenicity of melanoma B16F10.* Cancer biotherapy & radiopharmaceuticals, 1998. **13**(2): p. 121-131.
19. Chin, J.-E., et al., *Inhibitory effects of some medicinal plant extracts on the tyrosinase promoter activity on B16 mouse melanoma cells.* Advances in Traditional Medicine, 2000. **1**(2): p. 6-13.
20. Kaitin, K.I., *Deconstructing the drug development process: the new face of innovation.* Clinical Pharmacology & Therapeutics, 2010. **87**(3): p. 356-361.
21. Lavé, T., et al., *Challenges and opportunities with modelling and simulation in drug discovery and drug development.* Xenobiotica, 2007. **37**(10-11): p. 1295-1310.
22. Moore, S.W., *An overview of drug development in the United States and current challenges.* Southern medical journal, 2003. **96**(12): p. 1244-1256.

23. Zhang, L., M. Pfister, and B. Meibohm, *Concepts and challenges in quantitative pharmacology and model-based drug development.* The AAPS journal, 2008. **10**: p. 552-559.
24. Zorzi, G.K., et al., *On the use of nanotechnology-based strategies for association of complex matrices from plant extracts.* Revista Brasileira de Farmacognosia, 2015. **25**(4): p. 426-436.
25. Bonifacio, B.V., et al., *Nanotechnology-based drug delivery systems and herbal medicines: a review.* International journal of nanomedicine, 2014: p. 1-15.
26. Sleire, L., et al., *Drug repurposing in cancer.* Pharmacological research, 2017. **124**: p. 74-91.
27. Xia, Y., et al., *Drug repurposing for cancer therapy.* Signal Transduction and Targeted Therapy, 2024. **9**(1): p. 92.
28. Gonzalez-Fierro, A. and A. Dueñas-González, *Drug repurposing for cancer therapy, easier said than done.* Seminars in cancer biology, 2021. **68**: p. 123-131.
29. Dai, X., et al., *Dihydroartemisinin: a potential natural anticancer drug.* International journal of biological sciences, 2021. **17**(2): p. 603.
30. Lai, H. and N.P. Singh, *Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin.* Cancer letters, 1995. **91**(1): p. 41-46.
31. Li, Q., et al., *Dihydroartemisinin as a sensitizing agent in cancer therapies.* OncoTargets and therapy, 2021: p. 2563-2573.
32. Wong, K.H., et al., *Development of nanoscale drug delivery systems of dihydroartemisinin for cancer therapy: A review.* Asian Journal of Pharmaceutical Sciences, 2022. **17**(4): p. 475-490.
33. Chen, H., et al., *Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo.* Anti-cancer drugs, 2009. **20**(2): p. 131-140.
34. Wang, S.-J., et al., *Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway.* Cancer chemotherapy and pharmacology, 2011. **68**: p. 1421-1430.
35. Panche, A.N., A.D. Diwan, and S.R. Chandra, *Flavonoids: an overview.* Journal of nutritional science, 2016. **5**: p. e47.
36. Harborne, J.B. and T.J. Mabry, *The flavonoids: advances in research.* 2013(15): p. 165-176.
37. Grotewold, E., *The science of flavonoids.* 2006(21): p. 158-195.
38. Ganeshpurkar, A. and A. Saluja, *The pharmacological potential of hesperidin.* Indian Journal of Biochemistry & Biophysics, 2019. **56**: p. 287-300.
39. Aggarwal, V., et al., *Molecular mechanisms of action of hesperidin in cancer: Recent trends and advancements.* Experimental Biology and Medicine, 2020. **245**(5): p. 486-497.
40. Devi, K.P., et al., *Hesperidin: A promising anticancer agent from nature.* Industrial crops and products, 2015. **76**: p. 582-589.
41. Yap, K.M., et al., *Hesperidin and its aglycone hesperetin in breast cancer therapy: A review of recent developments and future prospects.* Saudi Journal of Biological Sciences, 2021. **28**(12): p. 6730-6747.
42. Pandey, P. and F. Khan, *A mechanistic review of the anticancer potential of hesperidin, a natural flavonoid from citrus fruits.* Nutrition Research, 2021. **92**: p. 21-31.
43. Birsu Cincin, Z., et al., *Anti-proliferative, apoptotic and signal transduction effects of hesperidin in non-small cell lung cancer cells.* Cellular Oncology, 2015. **38**: p. 195-204.

44. Yao, Y., et al., *Hesperidin inhibits lung cancer in vitro and in vivo through pinX1.* Frontiers in pharmacology, 2022. **13**: p. 918665.
45. Phung, C.D., et al., *PEGylated-paclitaxel and dihydroartemisinin nanoparticles for simultaneously delivering paclitaxel and dihydroartemisinin to colorectal cancer.* Pharmaceutical Research, 2020. **37**: p. 1-11.
46. Lu, Y., et al., *Self-assembled dihydroartemisinin nanoparticles as a platform for cervical cancer chemotherapy.* Drug Delivery, 2020. **27**(1): p. 876-887.
47. Omwoyo, W.N., et al., *Development, characterization and antimalarial efficacy of dihydroartemisinin loaded solid lipid nanoparticles.* Nanomedicine: Nanotechnology, Biology and Medicine, 2016. **12**(3): p. 801-809.
48. Sulaiman, G.M., et al., *Hesperidin loaded on gold nanoparticles as a drug delivery system for a successful biocompatible, anti-cancer, anti-inflammatory and phagocytosis inducer model.* Scientific reports, 2020. **10**(1): p. 9362.
49. Almukainzi, M., et al., *Chitosan/hesperidin nanoparticles for sufficient, compatible, antioxidant, and antitumor drug delivery systems.* Pharmaceuticals, 2024. **17**(8): p. 999.
50. Saad, S., et al., *Improved cardioprotective effects of hesperidin solid lipid nanoparticles prepared by supercritical antisolvent technology.* Colloids and Surfaces B: Biointerfaces, 2020. **187**: p. 110628.
51. Sahu, N., et al., *Synthesis of silver nanoparticles using flavonoids: hesperidin, naringin and diosmin, and their antibacterial effects and cytotoxicity.* International Nano Letters, 2016. **6**: p. 173-181.
52. Ren, G., et al., *Construction of reduction-sensitive heterodimer prodrugs of doxorubicin and dihydroartemisinin self-assembled nanoparticles with antitumor activity.* Colloids and Surfaces B: Biointerfaces, 2022. **217**: p. 112614.
53. Liu, K., et al., *Self-assembled targeted nanoparticles based on transferrin-modified eight-arm-polyethylene glycol–dihydroartemisinin conjugate.* Scientific Reports, 2016. **6**(1): p. 29461.
54. Kalluri, R. and V.S. LeBleu, *The biology, function, and biomedical applications of exosomes.* Science, 2020. **367**(6478): p. eaau6977.
55. Pegtel, D.M. and S.J. Gould, *Exosomes.* Annual review of biochemistry, 2019. **88**: p. 487-514.
56. Qin, J. and Q. Xu, *Functions and application of exosomes.* Acta Pol Pharm, 2014. **71**(4): p. 537-543.
57. Kalluri, R., *The biology and function of exosomes in cancer.* The Journal of clinical investigation, 2016. **126**(4): p. 1208-1215.
58. Rezaie, J., et al., *Exosomes and their application in biomedical field: difficulties and advantages.* Molecular neurobiology, 2018. **55**: p. 3372-3393.
59. Choi, H., et al., *Strategies for targeted delivery of exosomes to the brain: advantages and challenges.* Pharmaceutics, 2022. **14**(3): p. 672.
60. Kumar, D.N., et al., *Exosomes as emerging drug delivery and diagnostic modality for breast cancer: recent advances in isolation and application.* Cancers, 2022. **14**(6): p. 1435.
61. Corradetti, B., et al., *Exosomes as therapeutic systems*. 2021, Frontiers Media SA. p. 714743.
62. Diepgen, T.L. and V. Mahler, *The epidemiology of skin cancer.* British Journal of Dermatology, 2002. **146**(s61): p. 1-6.
63. Linares, M.A., A. Zakaria, and P. Nizran, *Skin cancer.* Prim Care, 2015. **42**(4): p. 645-659.

64. Madan, V., J.T. Lear, and R.-M. Szeimies, *Non-melanoma skin cancer.* The lancet, 2010. **375**(9715): p. 673-685.
65. Schadendorf, D., et al., *Melanoma.* Nature reviews Disease primers, 2015. **1**(1): p. 1-20.
66. Carr, S., C. Smith, and J. Wernberg, *Epidemiology and risk factors of melanoma.* Surgical Clinics, 2020. **100**(1): p. 1-12.
67. Dzwierzynski, W.W., *Melanoma risk factors and prevention.* Clinics in plastic surgery, 2021. **48**(4): p. 543-550.
68. Conforti, C. and I. Zalaudek, *Epidemiology and risk factors of melanoma: a review.* Dermatology Practical & Conceptual, 2021. **11**: p. 267-296.
69. Cho, E., B.A. Rosner, and G.A. Colditz, *Risk factors for melanoma by body site.* Cancer Epidemiology Biomarkers & Prevention, 2005. **14**(5): p. 1241-1244.
70. Davis, L.E., S.C. Shalin, and A.J. Tackett, *Current state of melanoma diagnosis and treatment.* Cancer biology & therapy, 2019. **20**(11): p. 1366-1379.
71. Rigel, D.S., J. Russak, and R. Friedman, *The evolution of melanoma diagnosis: 25 years beyond the ABCDs.* CA: a cancer journal for clinicians, 2010. **60**(5): p. 301-316.
72. Smaoui, N. and S. Bessassi, *A developed system for melanoma diagnosis.* International Journal of Computer Vision and Signal Processing, 2013. **3**(1): p. 10-17.
73. Fink, C. and H. Haenssle, *Non-invasive tools for the diagnosis of cutaneous melanoma.* Skin Research and Technology, 2017. **23**(3): p. 261-271.
74. Meng, X., et al., *Non-invasive optical methods for melanoma diagnosis.* Photodiagnosis and photodynamic therapy, 2021. **34**: p. 102266.
75. Elder, D.E., *Melanoma progression.* Pathology, 2016. **48**(2): p. 147-154.
76. Herlyn, M., *Human melanoma: development and progression.* Cancer and Metastasis Reviews, 1990. **9**: p. 101-112.
77. Rodolfo, M., M. Daniotti, and V. Vallacchi, *Genetic progression of metastatic melanoma.* Cancer letters, 2004. **214**(2): p. 133-147.
78. Hurt, M.A., *Types of melanoma?* Journal of the American Academy of Dermatology, 2008. **58**(6): p. 1059-1060.
79. Liu, Q., et al., *Targeted drug delivery to melanoma.* Advanced Drug Delivery Reviews, 2018. **127**: p. 208-221.
80. Hall, B.E., D. Bar-Sagi, and N. Nassar, *The structural basis for the transition from Ras-GTP to Ras-GDP.* Proceedings of the National Academy of Sciences, 2002. **99**(19): p. 12138-12142.
81. Marais, R., et al., *Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation.* The EMBO journal, 1995. **14**(13): p. 3136-3145.
82. Madhunapantula, S.V. and G.P. Robertson, *Is B-Raf a good therapeutic target for melanoma and other malignancies?* Cancer research, 2008. **68**(1): p. 5-8.
83. Robertson, G.P., *Functional and therapeutic significance of Akt deregulation in malignant melanoma.* Cancer and metastasis reviews, 2005. **24**(2): p. 273-285.
84. Hennessy, B.T., et al., *Exploiting the PI3K/AKT pathway for cancer drug discovery.* Nature reviews Drug discovery, 2005. **4**(12): p. 988-1004.
85. Domingues, B., et al., *Melanoma treatment in review.* ImmunoTargets and therapy, 2018: p. 35-49.
86. Curti, B.D. and M.B. Faries, *Recent advances in the treatment of melanoma.* New England Journal of Medicine, 2021. **384**(23): p. 2229-2240.
87. Eggermont, A.M. and J.M. Kirkwood, *Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?* European journal of cancer, 2004. **40**(12): p. 1825-1836.

88. Garbe, C. and K. Krasagakis, *Effects of interferons and cytokines on melanoma cells.* Journal of investigative dermatology, 1993. **100**(2): p. S239-S244.
89. Lugowska, I., P. Teterycz, and P. Rutkowski, *Immunotherapy of melanoma.* Contemporary Oncology/Współczesna Onkologia, 2018. **2018**(1): p. 61-67.
90. Kuryk, L., et al., *From conventional therapies to immunotherapy: melanoma treatment in review.* Cancers, 2020. **12**(10): p. 3057.
91. Achkar, T. and A.A. Tarhini, *The use of immunotherapy in the treatment of melanoma.* Journal of hematology & oncology, 2017. **10**: p. 1-9.
92. Mahoney, K.M., G.J. Freeman, and D.F. McDermott, *The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma.* Clinical therapeutics, 2015. **37**(4): p. 764-782.
93. Rossi, S., et al., *TNF-alpha and metalloproteases as key players in melanoma cells aggressiveness.* Journal of Experimental & Clinical Cancer Research, 2018. **37**: p. 1-17.
94. Gray-Schopfer, V., C. Wellbrock, and R. Marais, *Melanoma biology and new targeted therapy.* Nature, 2007. **445**(7130): p. 851-857.
95. B. Uzdensky, A., S. V. Demyanenko, and M. Y. Bibov, *Signal transduction in human cutaneous melanoma and target drugs.* Current cancer drug targets, 2013. **13**(8): p. 843-866.
96. Manzano, J.L., et al., *Resistant mechanisms to BRAF inhibitors in melanoma.* Annals of translational medicine, 2016. **4**(12): p. 237.
97. Hromic-Jahjefendic, A. and K. Lundstrom, *Viral vector-based melanoma gene therapy.* Biomedicines, 2020. **8**(3): p. 60.
98. Overgaard, J., *Radiation treatment of malignant melanoma.* International Journal of Radiation Oncology* Biology* Physics, 1980. **6**(1): p. 41-44.
99. Becker, J.C., et al., *Mouse models for melanoma: a personal perspective.* Experimental dermatology, 2010. **19**(2): p. 157-164.
100. Kuzu, O.F., et al., *Current state of animal (mouse) modeling in melanoma research.* Cancer growth and metastasis, 2015. **8**: p. CGM. S21214.
101. Beaumont, K.A., N. Mohana-Kumaran, and N.K. Haass, *Modeling melanoma in vitro and in vivo.* Healthcare, 2013. **2**(1): p. 27-46.
102. Björkdahl, O., et al., *Gene transfer of a hybrid interleukin-1β gene to B16 mouse melanoma recruits leucocyte subsets and reduces tumour growth in vivo.* Cancer immunology, immunotherapy, 1997. **44**: p. 273-281.
103. Combest, A.J., et al., *Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors.* The oncologist, 2012. **17**(10): p. 1303-1316.
104. Saleh, J., *Murine models of melanoma.* Pathology-Research and Practice, 2018. **214**(9): p. 1235-1238.
105. Pushpakom, S., et al., *Drug repurposing: progress, challenges and recommendations.* Nature reviews Drug discovery, 2019. **18**(1): p. 41-58.
106. Oprea, T.I., et al., *Drug repurposing from an academic perspective.* Drug Discovery Today: Therapeutic Strategies, 2011. **8**(3-4): p. 61-69.
107. Shieh, J.M., et al., *Activation of c-Jun N-terminal kinase is essential for mitochondrial membrane potential change and apoptosis induced by doxycycline in melanoma cells.* British journal of pharmacology, 2010. **160**(5): p. 1171-1184.
108. Grahovac, J., et al., *Telmisartan induces melanoma cell apoptosis and synergizes with vemurafenib in vitro by altering cell bioenergetics.* Cancer biology & medicine, 2019. **16**(2): p. 247.

109. Zhu, Y., et al., *Repurposing of the anti-helminthic drug niclosamide to treat melanoma and pulmonary metastasis via the STAT3 signaling pathway.* Biochemical pharmacology, 2019. **169**: p. 113610.
110. Gonzalez Maglio, D.H., et al., *Alterations in skin immune response throughout chronic UVB irradiation—Skin cancer development and prevention by naproxen.* Photochemistry and photobiology, 2010. **86**(1): p. 146-152.
111. Tomic, T., et al., *Metformin inhibits melanoma development through autophagy and apoptosis mechanisms.* Cell death & disease, 2011. **2**(9): p. e199-e199.
112. Parvathaneni, V., et al., *Drug repurposing: a promising tool to accelerate the drug discovery process.* Drug discovery today, 2019. **24**(10): p. 2076-2085.
113. Oprea, T. and J. Mestres, *Drug repurposing: far beyond new targets for old drugs.* The AAPS journal, 2012. **14**: p. 759-763.
114. Cortes, H., et al., *Repurposing of drug candidates for treatment of skin cancer.* Frontiers in oncology, 2021. **10**: p. 605714.
115. Kumbhar, P., et al., *Drug repurposing: An emerging strategy in alleviating skin cancer.* European Journal of Pharmacology, 2022. **926**: p. 175031.
116. Pérez Trueba, G., *Los flavonoides: antioxidantes o prooxidantes.* Revista Cubana de Investigaciones Biomédicas, 2003. **22**(1): p. 0-0.
117. Martínez-Flórez, S., et al., *Los flavonoides: propiedades y acciones antioxidantes.* Nutrición hospitalaria, 2002. **17**(6): p. 271-278.
118. Jiménez, C.I.E., E.Y.C. Martínez, and J.G. Fonseca, *Flavonoides y sus acciones antioxidantes.* Rev Fac Med UNAM, 2009. **52**(2): p. 73-5.
119. Agrawal, A., *Pharmacological activities of flavonoids: a review.* Int. J. Pharm. Sci. Nanotechnol, 2011. **4**(2): p. 1394-1398.
120. Wang, S.-H., Y.-L. Hu, and T.-X. Liu, *Plant distribution and pharmacological activity of flavonoids.* Tradit. Med. Res, 2019. **4**: p. 269-287.
121. Batra, P. and A.K. Sharma, *Anti-cancer potential of flavonoids: recent trends and future perspectives.* 3 Biotech, 2013. **3**: p. 439-459.
122. Woo, J.-S., et al., *Apigenin induces apoptosis by regulating Akt and MAPK pathways in human melanoma cell A375SM.* Molecular Medicine Reports, 2020. **22**(6): p. 4877-4889.
123. Hasnat, M.A., et al., *Apigenin attenuates melanoma cell migration by inducing anoikis through integrin and focal adhesion kinase inhibition.* Molecules, 2015. **20**(12): p. 21157-21166.
124. Zhao, G., et al., *Apigenin inhibits proliferation and invasion, and induces apoptosis and cell cycle arrest in human melanoma cells.* Oncology Reports, 2017. **37**(4): p. 2277-2285.
125. Das, S., et al., *Strategic formulation of apigenin-loaded PLGA nanoparticles for intracellular trafficking, DNA targeting and improved therapeutic effects in skin melanoma in vitro.* Toxicology letters, 2013. **223**(2): p. 124-138.
126. Xie, Q., et al., *Apigenin inhibits growth of melanoma by suppressing miR-512-3p and promoting the G1 phase of cell cycle involving the p27 Kip1 protein.* Molecular and Cellular Biochemistry, 2022. **477**(5): p. 1569-1582.
127. Zhang, X., et al., *Anti-melanogenic effects of epigallocatechin-3-gallate (EGCG), epicatechin-3-gallate (ECG) and gallocatechin-3-gallate (GCG) via down-regulation of cAMP/CREB/MITF signaling pathway in B16F10 melanoma cells.* Fitoterapia, 2020. **145**: p. 104634.
128. Bing-Xin, D., L. Pei, and L. Jun, *EGCG and ECG induce apoptosis and decrease autophagy via the AMPK/mTOR and PI3K/AKT/mTOR pathway in human melanoma cells.* Chinese Journal of Natural Medicines, 2022. **20**(4): p. 290-300.

129. Heo, J.-R., et al., *Phytochemical-induced reactive oxygen species and endoplasmic reticulum stress-mediated apoptosis and differentiation in malignant melanoma cells.* Phytomedicine, 2018. **39**: p. 100-110.
130. Yang, J., et al., *Anticancer effects of kaempferol in A375 human malignant melanoma cells are mediated via induction of apoptosis, cell cycle arrest, inhibition of cell migration and downregulation of m-TOR/PI3K/AKT pathway.* J. BUON, 2018. **23**(1): p. 218-223.
131. Qiang, D., et al., *Inhibitory effect of kaempferol on mouse melanoma cell line B16 in vivo and in vitro.* Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 2021. **38**(3): p. 498-504.
132. Choi, J., et al., *Naringenin exerts anticancer effects by inducing tumor cell death and inhibiting angiogenesis in malignant melanoma.* International journal of medical sciences, 2020. **17**(18): p. 3049.
133. Bouzaiene, N.N., et al., *Effect of apigenin-7-glucoside, genkwanin and naringenin on tyrosinase activity and melanin synthesis in B16F10 melanoma cells.* Life sciences, 2016. **144**: p. 80-85.
134. Vaid, M., et al., *Silymarin targets β-catenin signaling in blocking migration/invasion of human melanoma cells.* PloS one, 2011. **6**(7): p. e23000.
135. Martinez-Perez, C., et al., *Novel flavonoids as anti-cancer agents: mechanisms of action and promise for their potential application in breast cancer.* Biochemical Society Transactions, 2014. **42**(4): p. 1017-1023.
136. Liu, H.L., W.B. Jiang, and M.X. Xie, *Flavonoids: recent advances as anticancer drugs.* Recent patents on anti-cancer drug discovery, 2010. **5**(2): p. 152-164.
137. Kopustinskiene, D.M., et al., *Flavonoids as anticancer agents.* Nutrients, 2020. **12**(2): p. 457.
138. Pulito, C., S. Strano, and G. Blandino, *Dihydroartemisinin: from malaria to the treatment of relapsing head and neck cancers.* Annals of Translational Medicine, 2020. **8**(10).
139. Chen, H.-H., et al., *Antimalarial dihydroartemisinin also inhibits angiogenesis.* Cancer chemotherapy and pharmacology, 2004. **53**: p. 423-432.
140. Xu, C.-H., et al., *Dihydroartemisinin treatment exhibits antitumor effects in glioma cells through induction of apoptosis.* Molecular Medicine Reports, 2017. **16**(6): p. 9528-9532.
141. Xia, T., et al., *Dihydroartemisinin induces cell apoptosis through repression of UHRF1 in prostate cancer cells.* Anti-Cancer Drugs, 2022. **33**(1): p. e113-e124.
142. Shen, Y., et al., *Iron promotes dihydroartemisinin cytotoxicity via ROS production and blockade of autophagic flux via lysosomal damage in osteosarcoma.* Frontiers in pharmacology, 2020. **11**: p. 444.
143. Lin, R., et al., *Dihydroartemisinin (DHA) induces ferroptosis and causes cell cycle arrest in head and neck carcinoma cells.* Cancer letters, 2016. **381**(1): p. 165-175.
144. Zhang, T., et al., *Dihydroartemisinin regulates the immune system by promotion of CD8+ T lymphocytes and suppression of B cell responses.* Science China Life Sciences, 2020. **63**: p. 737-749.
145. Li, Z., et al., *Dihydroartemisinin inhibits melanoma migration and metastasis by affecting angiogenesis.* Phytotherapy Research, 2023. **12**: p. 421-439.
146. Yu, R., et al., *Dihydroartemisinin inhibits melanoma by regulating CTL/Treg anti-tumor immunity and STAT3-mediated apoptosis via IL-10 dependent manner.* Journal of Dermatological Science, 2020. **99**(3): p. 193-202.
147. Zhang, M., et al., *Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways*

Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors. Journal of Immunology Research, 2022. **2022**(1): p. 2253436.
148. Cabello, C.M., et al., *The redox antimalarial dihydroartemisinin targets human metastatic melanoma cells but not primary melanocytes with induction of NOXA-dependent apoptosis.* Investigational new drugs, 2012. **30**: p. 1289-1301.
149. Shi, X., et al., *Dihydroartemisinin, an antimalarial drug, induces absent in melanoma 2 inflammasome activation and autophagy in human hepatocellular carcinoma HepG2215 cells.* Phytotherapy Research, 2019. **33**(5): p. 1413-1425.
150. Zhang, Q., et al., *Inhibitory effect of dihydroartemisinin on the proliferation and migration of melanoma cells and experimental lung metastasis from melanoma in mice.* Frontiers in Pharmacology, 2021. **12**: p. 727275.
151. Li, Z., et al., *Dihydroartemisinin Regulates Self-Renewal of Human Melanoma-Initiating Cells by Targeting PKM2/LDHA-Related Glycolysis.* Eurasian Journal of Medicine and Oncology, 2024. **8**(2): p. 225-232.
152. Garg, A., et al., *Chemistry and pharmacology of the citrus bioflavonoid hesperidin.* Phytotherapy research, 2001. **15**(8): p. 655-669.
153. Pyrzynska, K., *Hesperidin: A review on extraction methods, stability and biological activities.* Nutrients, 2022. **14**(12): p. 2387.
154. Roohbakhsh, A., et al., *Molecular mechanisms behind the biological effects of hesperidin and hesperetin for the prevention of cancer and cardiovascular diseases.* Life sciences, 2015. **124**: p. 64-74.
155. Rahmani, A.H., A.Y. Babiker, and S. Anwar, *Hesperidin, a bioflavonoid in cancer therapy: a review for a mechanism of action through the modulation of cell signaling pathways.* Molecules, 2023. **28**(13): p. 5152.
156. de Oliveira, J.M.P.F., C. Santos, and E. Fernandes, *Therapeutic potential of hesperidin and its aglycone hesperetin: Cell cycle regulation and apoptosis induction in cancer models.* Phytomedicine, 2020. **73**: p. 152887.
157. Rodrigues, C.V. and M. Pintado, *Hesperidin from orange peel as a promising skincare bioactive: an overview.* International Journal of Molecular Sciences, 2024. **25**(3): p. 1890.
158. Li, M., et al., *Hesperidin ameliorates UV radiation-induced skin damage by abrogation of oxidative stress and inflammatory in HaCaT cells.* Journal of Photochemistry and Photobiology B: Biology, 2016. **165**: p. 240-245.
159. Vabeiryureilai, M., K. Lalrinzuali, and G.C. Jagetia, *Chemopreventive effect of hesperidin, a citrus bioflavonoid in two stage skin carcinogenesis in Swiss albino mice.* Heliyon, 2019. **5**(10): p. 256-271.
160. Man, M.-Q., B. Yang, and P.M. Elias, *Benefits of hesperidin for cutaneous functions.* Evidence-Based Complementary and Alternative Medicine, 2019. **2019**(1): p. 2676307.
161. Boojar, M.M.A., et al., *Ceramide generation as a novel biological mechanism for chemo-preventive and cytotoxic effects of hesperidin on HT-144 melanoma cells.* Beni-Suef University journal of basic and applied sciences, 2018. **7**(4): p. 640-645.
162. Choi, E.O., et al., *Citrus unshiu peel suppress the metastatic potential of murine melanoma B16F10 cells in vitro and in vivo.* Phytotherapy Research, 2019. **33**(12): p. 3228-3241.
163. Byun, E.-B., et al., *Hesperidin structurally modified by gamma irradiation induces apoptosis in murine melanoma B16BL6 cells and inhibits both subcutaneous tumor growth and metastasis in C57BL/6 mice.* Food and Chemical Toxicology, 2019. **127**: p. 19-30.

164. Théry, C., L. Zitvogel, and S. Amigorena, *Exosomes: composition, biogenesis and function.* Nature reviews immunology, 2002. **2**(8): p. 569-579.
165. Chen, B.-Y., et al., *Advances in exosomes technology.* Clinica chimica acta, 2019. **493**: p. 14-19.
166. Orobets, V. and E. Kastarnova, *The advantage of exosomes as vectors of drugs.* European Journal of Natural History, 2015(4): p. 54-55.
167. Nam, G.H., et al., *Emerging prospects of exosomes for cancer treatment: from conventional therapy to immunotherapy.* Advanced Materials, 2020. **32**(51): p. 2002440.
168. Kumar, D.N., et al., *Exosomes improved the in vitro anti-melanoma efficacy of dihydroartemisinin.* Journal of Drug Delivery Science and Technology, 2024. **99**: p. 105957.
169. Théry, C., et al., *Isolation and characterization of exosomes from cell culture supernatants and biological fluids.* Current protocols in cell biology, 2006. **30**(1): p. 3.22. 1-3.22. 29.
170. Cheruvanky, A., et al., *Rapid isolation of urinary exosomal biomarkers using a nanomembrane ultrafiltration concentrator.* American Journal of Physiology-Renal Physiology, 2007. **292**(5): p. F1657-F1661.
171. Gardiner, C., et al., *Techniques used for the isolation and characterization of extracellular vesicles: results of a worldwide survey.* Journal of extracellular vesicles, 2016. **5**(1): p. 32945.
172. Nakai, W., et al., *A novel affinity-based method for the isolation of highly purified extracellular vesicles.* Scientific reports, 2016. **6**(1): p. 1-11.
173. Baber, N., *International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH).* British journal of clinical pharmacology, 1994. **37**(5): p. 401.
174. Munagala, R., et al., *Bovine milk-derived exosomes for drug delivery.* Cancer letters, 2016. **371**(1): p. 48-61.
175. Mohapatra, D., et al., *Quality by design–based development and optimization of fourth-generation ternary solid dispersion of standardized Piper longum extract for melanoma therapy.* Drug Delivery and Translational Research, 2023. **13**(12): p. 3094-3131.
176. Urimi, D., et al., *Polyglutamic acid functionalization of chitosan nanoparticles enhances the therapeutic efficacy of insulin following oral administration.* AAPS PharmSciTech, 2019. **20**: p. 1-14.
177. Kim, M.S., et al., *Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells.* Nanomedicine: Nanotechnology, Biology and Medicine, 2016. **12**(3): p. 655-664.
178. Singh, S., et al., *Insulin-and quercetin-loaded liquid crystalline nanoparticles: implications on oral bioavailability, antidiabetic and antioxidant efficacy.* Nanomedicine, 2018. **13**(5): p. 521-537.
179. Kushwah, V., et al., *Co-delivery of docetaxel and gemcitabine using PEGylated self-assembled stealth nanoparticles for improved breast cancer therapy.* Nanomedicine: Nanotechnology, Biology and Medicine, 2018. **14**(5): p. 1629-1641.
180. Anjum, M.M., et al., *Development of Anacardic Acid/hydroxypropyl-β-cyclodextrin inclusion complex with enhanced solubility and antimicrobial activity.* Journal of Molecular Liquids, 2019. **296**: p. 112085.
181. Agrawal, A.K., et al., *"Liquid crystalline nanoparticles": rationally designed vehicle to improve stability and therapeutic efficacy of insulin following oral administration.* Molecular Pharmaceutics, 2017. **14**(6): p. 1874-1882.

182. Agrawal, A.K., et al., *Folate appended chitosan nanoparticles augment the stability, bioavailability and efficacy of insulin in diabetic rats following oral administration.* RSC Advances, 2015. **5**(127): p. 105179-105193.
183. Di Pace, A.L., et al., *Characterization of human NK cell-derived exosomes: role of DNAM1 receptor in exosome-mediated cytotoxicity against tumor.* Cancers, 2020. **12**(3): p. 661.
184. Kumar, D.N., et al., *Combination therapy comprising paclitaxel and 5-fluorouracil by using folic acid functionalized bovine milk exosomes improves the therapeutic efficacy against breast cancer.* Life, 2022. **12**(8): p. 1143.
185. Jiang, L., et al., *Engineering exosomes endowed with targeted delivery of triptolide for malignant melanoma therapy.* ACS applied materials & interfaces, 2021. **13**(36): p. 42411-42428.
186. Chary, P.S., et al., *Design, fabrication and evaluation of stabilized polymeric mixed micelles for effective management in cancer therapy.* Pharmaceutical Research, 2022. **39**(11): p. 2761-2780.
187. Kumar, D.N., et al., *Enhanced Therapeutic Efficacy Against Melanoma through Exosomal Delivery of Hesperidin.* Molecular Pharmaceutics, 2024: p. 3061-3076.
188. Calabria, E., et al., *ASCs-exosomes recover coupling efficiency and mitochondrial membrane potential in an in vitro model of ALS.* Frontiers in Neuroscience, 2019. **13**: p. 1070.
189. Zhang, J., et al., *Dihydroartemisinin affects STAT3/DDA1 signaling pathway and reverses breast cancer resistance to cisplatin.* The American Journal of Chinese Medicine, 2023. **51**(02): p. 445-459.
190. Ju, R.-J., et al., *Octreotide-modified liposomes containing daunorubicin and dihydroartemisinin for treatment of invasive breast cancer.* Artificial cells, nanomedicine, and biotechnology, 2018. **46**(sup1): p. 616-628.
191. Minocha, T., et al., *Melatonin induces apoptosis and cell cycle arrest in cervical cancer cells via inhibition of NF-κB pathway.* Inflammopharmacology, 2022. **30**(4): p. 1411-1429.
192. Saneja, A., et al., *Development and evaluation of long-circulating nanoparticles loaded with betulinic acid for improved anti-tumor efficacy.* International journal of pharmaceutics, 2017. **531**(1): p. 153-166.
193. Penfornis, P., et al., *Extracellular vesicles as carriers of microRNA, proteins and lipids in tumor microenvironment.* International journal of cancer, 2016. **138**(1): p. 14-21.
194. Liang, L., et al., *Treatment for hepatocellular carcinoma is enhanced when norcantharidin is encapsulated in exosomes derived from bone marrow mesenchymal stem cells.* Molecular Pharmaceutics, 2021. **18**(3): p. 1003-1013.
195. Hussein, M.R., A.K. Haemel, and G.S. Wood, *Apoptosis and melanoma: molecular mechanisms.* The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland, 2003. **199**(3): p. 275-288.
196. Von Schuckmann, L.A., et al., *Risk of melanoma recurrence after diagnosis of a high-risk primary tumor.* JAMA dermatology, 2019. **155**(6): p. 688-693.
197. Haass, N.K., et al., *Adhesion, migration and communication in melanocytes and melanoma.* Pigment cell research, 2005. **18**(3): p. 150-159.
198. Dong, J., et al., *Effect of dihydroartemisinin on epithelial-to-mesenchymal transition in canine mammary tumour cells.* Research in veterinary science, 2019. **124**: p. 240-247.

199. Yao, Y., et al., *Artemisinin derivatives inactivate cancer-associated fibroblasts through suppressing TGF-β signaling in breast cancer.* Journal of Experimental & Clinical Cancer Research, 2018. **37**: p. 1-14.
200. Wu, B., et al., *Dihydroartiminisin inhibits the growth and metastasis of epithelial ovarian cancer.* Oncology reports, 2012. **27**(1): p. 101-108.
201. Hou, J., et al., *Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action.* Clinical cancer research, 2008. **14**(17): p. 5519-5530.
202. Kumar, D.N., et al., *Impact of the drug loading method on the drug distribution and biological efficacy of exosomes.* Aaps Pharmscitech, 2023. **24**(6): p. 166.
203. Qi, H., et al., *Exosomes derived from mesenchymal stem cells inhibit mitochondrial dysfunction-induced apoptosis of chondrocytes via p38, ERK, and Akt pathways.* In Vitro Cellular & Developmental Biology-Animal, 2019. **55**: p. 203-210.
204. Agrawal, A.K., et al., *Milk-derived exosomes for oral delivery of paclitaxel.* Nanomedicine: Nanotechnology, Biology and Medicine, 2017. **13**(5): p. 1627-1636.
205. Wang, Z. and C.H. Yu, *Preparation and growth characteristics of mesocarbon microbeads.* Advanced Materials Research, 2013. **750**: p. 1121-1124.
206. Wallen, M., et al., *Milk/colostrum exosomes: A nanoplatform advancing delivery of cancer therapeutics.* Cancer letters, 2023. **561**: p. 216141.
207. Hajipour, H., et al., *A human chorionic gonadotropin (hCG) delivery platform using engineered uterine exosomes to improve endometrial receptivity.* Life sciences, 2021. **275**: p. 119351.
208. Kashkooli, F.M., M. Soltani, and M. Souri, *Controlled anti-cancer drug release through advanced nano-drug delivery systems: Static and dynamic targeting strategies.* Journal of controlled release, 2020. **327**: p. 316-349.
209. Valkenburg, K.C., et al., *Wnt/β-catenin signaling in normal and cancer stem cells.* Cancers, 2011. **3**(2): p. 2050-2079.
210. Aqil, F., et al., *Exosomes for the enhanced tissue bioavailability and efficacy of curcumin.* The AAPS journal, 2017. **19**: p. 1691-1702.
211. Jeong, S.A., et al., *Hesperidin suppresses the proliferation of prostate cancer cells by inducing oxidative stress and disrupting Ca2+ homeostasis.* Antioxidants, 2022. **11**(9): p. 1633.
212. Elefantova, K., et al., *Detection of the mitochondrial membrane potential by the cationic dye JC-1 in L1210 cells with massive overexpression of the plasma membrane ABCB1 drug transporter.* International journal of molecular sciences, 2018. **19**(7): p. 1985.
213. Park, H., et al., *Apoptotic effect of hesperidin through caspase3 activation in human colon cancer cells, SNU-C4.* Phytomedicine, 2008. **15**(1-2): p. 147-151.
214. Zhang, J., et al., *Hesperetin induces the apoptosis of hepatocellular carcinoma cells via mitochondrial pathway mediated by the increased intracellular reactive oxygen species, ATP and calcium.* Medical Oncology, 2015. **32**: p. 1-11.
215. Panneerselvam, J., et al., *IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis.* PloS one, 2015. **10**(3): p. e0122439.
216. Ramsey, D.M. and S.R. McAlpine, *Halting metastasis through CXCR4 inhibition.* Bioorganic & medicinal chemistry letters, 2013. **23**(1): p. 20-25.
217. Kamaraj, S., et al., *Modulatory effect of hesperidin on benzo (a) pyrene induced experimental lung carcinogenesis with reference to COX-2, MMP-2 and MMP-9.* European journal of pharmacology, 2010. **649**(1-3): p. 320-327.
218. Singh, B., et al., *COX-2 overexpression increases motility and invasion of breast cancer cells.* International journal of oncology, 2005. **26**(5): p. 1393-1399.

219. Nalla, A.K., et al., *Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells.* Cancer gene therapy, 2010. **17**(9): p. 599-613.
220. Mittal, A., S. Tabasum, and R.P. Singh, *Berberine in combination with doxorubicin suppresses growth of murine melanoma B16F10 cells in culture and xenograft.* Phytomedicine, 2014. **21**(3): p. 340-347.
221. Marsh, J.C., *Hepatic vascular toxicity of dacarbazine (DTIC): not a rare complication.* Hepatology, 1989. **9**(5): p. 790-792.

Appendices

9 Appendices

9.1 Appendix A: Institutional Animal Ethics Committee (IAEC) certificates

भारतीय प्रौद्योगिकी संस्थान
काशी हिन्दू विश्वविद्यालय
IIT INDIAN INSTITUTE OF TECHNOLOGY
BANARAS HINDU UNIVERSITY

Department of Pharmaceutical Engineering & Technology

Regd. No. 2123/GO/Re/S/21/CPCSEA Date: 09 February, 2023

IAEC Approval Number: **IIT(BHU)/IAEC/2023/002**

CERTIFICATE

This is to certify that the project proposal entitled **"Oral delivery of dihydroartemisinin in the management of melanoma cancer"** submitted by **Mr. Dulla Naveen Kumar** under supervision of **Dr. Ashish Kumar Agrawal** has been approved/recommended by the IAEC of *Indian Institute of Technology, Banaras Hindu University, Varanasi* in its meeting dated **09/02/2023** and has been sanctioned **50 Swiss Albino Mice (Female)** under this proposal for a duration of **Twelve (12) months.**

Prof. Vikash Kumar Dubey	Dr. Vinod Tiwari	Dr. Shesh Narayan Mishra
Name & Signature	**Name & Signature**	**Name & Signature**
Chairman	**Member Secretary**	**Main Nominee of CPCSEA**

Note: The CPCSEA Guideline should be followed strictly while handling the animals.

भारतीय प्रौद्योगिकी संस्थान
काशी हिन्दू विश्वविद्यालय

IIT INDIAN INSTITUTE OF TECHNOLOGY
BANARAS HINDU UNIVERSITY

Department of Pharmaceutical Engineering & Technology

Regd. No. 2123/GO/Re/S/21/CPCSEA

Date: 15 February, 2024

IAEC Approval Number: **IIT(BHU)/IAEC/2024/I/003**

CERTIFICATE

This is to certify that the project proposal entitled "***Oral delivery of Hesperidin in the management of melanoma cancer***" submitted by **Mr. Naveen Kumar Dulla** under the supervision of **Dr. Ashish Kumar Agrawal** has been approved/recommended by the IAEC the of Indian Institute of Technology, Banaras Hindu University, Varanasi in its meeting dated **15 February, 2024** and has been sanctioned 30 **(M/F) Swiss Albino Mice** and 10 **(M/F) Sprague -Dawley Rats** under this proposal for a duration of **12 (Twelve) months.**

Prof. Vikash Kumar Dubey	Dr. Vinod Tiwari	Dr. Shesh Narayan Mishra
Name & Signature	**Name & Signature**	**Name & Signature**
Chairman	**Member Secretary**	**Main Nominee of CPCSEA**

Chairperson
Institutional Animals Ethics Committee
IIT (BHU), Varanasi-221005

Member Secretory
Institutional Animals Ethics Committee
IIT (BHU), Varanasi-221005

Note: The CPCSEA Guideline should be followed strictly while handling the animal

9.2 Appendix B: Publications

9.2.1 List of publications from thesis works

1) **Dulla Naveen Kumar**, Aiswarya Chaudhuri, Deepa Dehari, Armin M Gamper, Dinesh Kumar, Ashish K Agrawal. “Exosomes Improved the in Vitro Anti-Melanoma Efficacy of Dihydroartemisinin”. Journal of Drug Delivery Science and Technology 2024. https://doi.org/10.1016/j.jddst.2024.105957
2) **Dulla Naveen Kumar**, Aiswarya Chaudhuri, Deepa Dehari, Armin M Gamper, Dinesh Kumar, Ashish K Agrawal. “Oral delivery of dihydroartemisinin for the treatment of melanoma via bovine milk exosomes”. Under communication in Drug Delivery and Translational Research, 2024.
3) **Dulla Naveen Kumar**, Aiswarya Chaudhuri, Deepa Dehari, Armin M. Gamper, Dinesh Kumar, and Ashish Kumar Agrawal. "Enhanced Therapeutic Efficacy Against Melanoma through Exosomal Delivery of Hesperidin." Molecular Pharmaceutics 2024. https://doi.org/10.1021/acs.molpharmaceut.4c00490

9.2.2 List of other publications during Ph.D

1. **Dulla Naveen Kumar,** Aiswarya Chaudhuri, Dinesh Kumar, Sanjay Singh, and Ashish Kumar Agrawal. "Impact of the drug loading method on the drug distribution and biological efficacy of exosomes." ***AAPS PharmSciTech*** 24, no. 6 (2023). https://doi.org/10.1208/s12249-023-02624-6
2. **Dulla Naveen Kumar,** Aiswarya Chaudhuri, Farrukh Aqil, Deepa Dehari, Radha Munagala, Sanjay Singh, Ramesh C Gupta, Ashish Kumar Agrawal, Exosomes as Emerging Drug Delivery and Diagnostic Modality for Breast Cancer: Recent Advances in Isolation and Application. **Cancers,** 2022. https://doi.org/10.3390/cancers14061435

3. **Dulla Naveen Kumar**, Aiswarya Chaudhuri, Deepa Dehari, Anusmita Shekher, Subash C Gupta, Shreyasi Majumdar, Sairam Krishnamurthy, Sanjay Singh, Dinesh Kumar, Ashish Kumar Agrawal, Combination therapy comprising paclitaxel and 5-fluorouracil by using folic acid functionalized bovine milk exosomes improves the therapeutic efficacy against breast cancer. **Life,** 2022. https://doi.org/10.3390/life12081143
4. **Dulla Naveen Kumar**, Aiswarya Chaudhuri, Deepa Dehari, Armin M Gamper, Dinesh Kumar, Ashish K Agrawal. **"**An investigation of in vitro anti-cancer efficacy of dihydroartemisinin-loaded bovine milk exosomes against triple-negative breast cancer". **The AAPS Journal** 2024. https://doi.org/10.1208/s12248-024-00958-y
5. Chaudhuri, Aiswarya, **Dulla Naveen Kumar**, Dinesh Kumar, and Ashish Kumar Agrawal. "Functionalized solid lipid nanoparticles combining docetaxel and erlotinib synergize the anticancer efficacy against triple-negative breast cancer."**European Journal of Pharmaceutics and Biopharmaceutics** (2024). https://doi.org/10.1016/j.ejpb.2024.114386
6. Aiswarya Chaudhuri, **Dulla Naveen Kumar**, Saurabh Kumar Srivastava, Dinesh Kumar, Umesh Kumar Patil, Avanish Singh Parmar, Sanjay Singh and Ashish Kumar Agrawal "Combinatorial Delivery of Docetaxel and Erlotinib Loaded 2 Functionalized Nanostructured Lipid Carriers for the 3 Treatment of Triple-Negative Breast Cancer Using Quality by 4 Design Approach" **Pharmaceutics (2024).** https://doi.org/10.3390/pharmaceutics16070926
7. Dehari, Deepa, **Dulla Naveen Kumar**, Aiswarya Chaudhuri, Akshay Kumar, Rajesh Kumar, Dinesh Kumar, Sanjay Singh, Gopal Nath, and Ashish Kumar Agrawal. "Bacteriophage entrapped chitosan microgel for the treatment of biofilm-mediated polybacterial infection in burn wounds." **International Journal of Biological Macromolecules** 253 (2023). https://doi.org/10.1016/j.ijbiomac.2023.127247

8. Anjum, Md Meraj, **Dulla Naveen Kumar**, Sankha Bhattacharya, Krishna Kumar Patel, Mahalingam Rajamanickam Vijayakumar, Ashish Kumar Agrawal, and Sanjay Singh. "Topical delivery of cyclodextrin crosslinked nanosponge of anacardic acid for treatment of UV-B induced skin photoaging: Formulation, characterization and biochemical estimation." **Journal of Drug Delivery Science and Technology** 87 (2023). https://doi.org/10.1016/j.jddst.2023.104840
9. Dehari, Deepa, Aiswarya Chaudhuri, **Dulla Naveen Kumar**, Meraj Anjum, Rajesh Kumar, Akshay Kumar, Dinesh Kumar, Gopal Nath, and Ashish Kumar Agrawal. "A bacteriophage-loaded microparticle laden topical gel for the treatment of multidrug-resistant biofilm-mediated burn wound infection." **AAPS PharmSciTech** 24, no. 6 (2023). https://doi.org/10.1208/s12249-023-02620-w
10. Dehari, Deepa, Aiswarya Chaudhuri, **Dulla Naveen Kumar**, Rohit Patil, Mayank Gangwar, Sonam Rastogi, Dinesh Kumar, Gopal Nath, and Ashish Kumar Agrawal. "A Bacteriophage Microgel Effectively Treats the Multidrug-Resistant Acinetobacter baumannii Bacterial Infections in Burn Wounds." **Pharmaceuticals** 16, no. 7 (2023). https://doi.org/10.3390/ph16070942
11. Mohapatra, Debadatta, **Dulla Naveen Kumar**, Singh Shreya, Vivek Pandey, Pawan K. Dubey, Ashish Kumar Agrawal, and Alakh N. Sahu. "Quality by design–based development and optimization of fourth-generation ternary solid dispersion of standardized Piper longum extract for melanoma therapy." **Drug Delivery and Translational Research** (2023). https://doi.org/10.1007/s13346-023-01375-y
12. Mohapatra, Debadatta, **Dulla Naveen Kumar**, Singh Shreya, Dhananjay Panigrahi, Ashish Kumar Agrawal, and Alakh N. Sahu. "Quality-by-design-based development of ultradeformable nanovesicular transgelosome of standardized Piper longum extract for melanoma." **Nanomedicine** 18, no. 14 (2023). https://doi.org/10.2217/nnm-2023-0069

13. Patil, Rohit, Deepa Dehari, Aiswarya Chaudhuri, **Dulla Naveen Kumar**, Dinesh Kumar, Sanjay Singh, Gopal Nath, and Ashish Kumar Agrawal. "Recent advancements in nanotechnology-based Bacteriophage delivery strategies against bacterial ocular infections." **Microbiological Research** (2023). https://doi.org/10.1016/j.micres.2023.127413
14. Priyanka Karunanidhi, Nitin Verma, **Dulla Naveen Kumar**, Ashish Kumar Agrawal, Sanjay Singh, Triphenylphosphonium functionalized Ficus religiosa L. extract loaded nanoparticles improve the mitochondrial function in oxidative stress induced diabetes. **AAPS PharmSciTech,** 22(5). https://doi.org/10.1208/s12249-021-02016-8
15. Singh Shreya, **Dulla Naveen Kumar**, Debadatta Mohapatra, Shivani Jaiswal, Gaurav Gopal Naik, Santosh Kumar Guru, Ashish Kumar Agarwal, Senthil Raja Ayyannan, Alakh N Sahu, Tracing the Anti-cancer Mechanism of Pleurotus osteratus by the Integrative Approach of Network Pharmacology and Experimental Studies. **Applied Biochemistry and Biotechnology,** 2022 . https://doi.org/10.1007/s12010-022-04111-3
16. Shloka Negi, Aiswarya Chaudhuri, **Dulla Naveen Kumar**, Deepa Dehari, Sanjay Singh, Ashish Kumar Agrawal, Nanotherapeutics in autophagy: A paradigm shift in cancer treatment. **Drug Delivery and Translational Research,** 1-24, 2022. **https://doi.org/10.1007/s13346-022-01125-6**
17. Aiswarya Chaudhuri, **Dulla Naveen Kumar**, Deepa Dehari, Sanjay Singh, Pradeep Kumar, Pradeep Kumar Bolla, Dinesh Kumar, Ashish Kumar Agrawal, Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC). Pharmaceuticals**,** 542, 2022. https://doi.org/10.3390/ph15050542
18. Aiswarya Chaudhuri, **Dulla Naveen Kumar**, Rasheed A Shaik, Basma G Eid, Ashraf B Abdel-Naim, Shadab Md, Aftab Ahmad, Ashish Kumar Agrawal, Lipid-Based Nanoparticles as a Pivotal Delivery Approach in Triple Negative Breast Cancer

(TNBC) Therapy. **International Journal of Molecular Sciences**, 23, 2022. https://doi.org/10.3390/ijms231710068

19. Aditya Vivek Joglekar, Deepa Dehari, Md Anjum, **Naveen Dulla**, Aiswarya Chaudhuri, Sanjay Singh, Ashish Kumar Agrawal, Therapeutic potential of venom peptides: Insights in the nanoparticle-mediated venom formulations. **Future Journal of Pharmaceutical Sciences**,1, 2022. https://doi.org/10.1186/s43094-022-00415-7
20. Aiswarya Chaudhuri, Korra Ramesh, **Dulla Naveen Kumar**, Deepa Dehari, Sanjay Singh, Dinesh Kumar, Ashish Kumar Agrawal, Polymeric micelles: A novel drug delivery system for the treatment of breast cancer. Journal of Drug Delivery Science and Technology, 108(9), 2019. https://doi.org/10.1016/j.jddst.2022.103886
21. Chaudhuri, Aiswarya, **Dulla Naveen Kumar**, Deepa Dehari, Rohit Patil, Sanjay Singh, Dinesh Kumar, and Ashish Kumar Agrawal. "Endorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology." **Cancers** 15, no. 9 (2023). https://doi.org/10.3390/cancers15092661

Book Chapter

22. Md Meraj Anjum, **Dulla Naveen Kumar**, Aiswarya Chaudhuri, Sanjay Singh, Ashish Kumar Agrawal, (2022) Extracellular Vesicles for Nucleic Acid Delivery: Progress and Prospects for Safe RNA-Based Gene Therapy, CRC Press, USA. 10.1201/9781003186083
23. Dehari, Deepa, Aiswarya Chaudhuri, **Dulla Naveen Kumar**, Gopal Nath, and Ashish Kumar Agrawal. "Fiber and textile in drug delivery to combat multidrug resistance microbial infection." **In Fiber and Textile Engineering in Drug Delivery Systems**, pp. 359-387. Woodhead Publishing, 2023. https://doi.org/10.1016/B978-0-323-96117-2.00006-6